ArticleImmunity2025
The transcriptional repressor BLIMP1 enforces TCF-1-dependent and -independent restriction of the memory fate of CD8
Abstract read
In one paragraph
Article in Immunity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- DC-intrinsic SHP1 restrains central memory CD8⁺ T cell formation via the TCF-1/Wnt/β-Catenin axis.Medical oncology (Northwood, London, England) · 2026Article
- Single-cell gain-of-function mapping reveals latent regulatory programs governing CD8Research square · 2026Article
- PRDM Proteins Orchestrate Colorectal Cancer Tumorigenesis.International journal of molecular sciences · 2026Review
- High efficiency CRISPR knock-in demonstrates that TCF1 is insufficient to reverse T cell exhaustion.Nature communications · 2026Article
- Advances in IL-2 Family Cytokine-Based Cancer Therapies: Overcoming Challenges Through Molecular Engineering and Delivery Strategies.Immune network · 2026Review
- Latent Regulatory Programs Generate Synthetic T Cell States with Enhanced Therapeutic Potential.bioRxiv : the preprint server for biology · 2026Article
- Stem-like T cells in cancer immunotherapy: biology, regulation and therapeutic targeting.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Maegan K MurphyDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Matthew McCullenDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA; Department of Microbial Infection and Immunity, The Ohio State University College of Medicine, Columbus, OH, USA.
Joshua L DeffenbaughDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Andy Y ChenDepartment of Pathology, Stanford University, Stanford, CA, USA; Department of Bioengineering, Stanford University, Stanford, CA, USA.
Joy PaiDepartment of Pathology, Stanford University, Stanford, CA, USA; Department of Immunology, Stanford University, Stanford, CA, USA.
Bence DanielDepartment of Pathology, Stanford University, Stanford, CA, USA.
Amir YousifDepartment of Microbial Infection and Immunity, The Ohio State University College of Medicine, Columbus, OH, USA.
Saravanan RajuDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Sunnie HsiungDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Zhenxiao WangDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Hazem E GhoneimDepartment of Microbial Infection and Immunity, The Ohio State University College of Medicine, Columbus, OH, USA; Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Ansuman T SatpathyDepartment of Pathology, Stanford University, Stanford, CA, USA; Department of Bioengineering, Stanford University, Stanford, CA, USA; Department of Immunology, Stanford University, Stanford, CA, USA; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA; Stanford Cancer Institute, Stanford University, Stanford, CA, USA; Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
Marco ColonnaDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Eugene M OltzDepartment of Microbial Infection and Immunity, The Ohio State University College of Medicine, Columbus, OH, USA; Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Takeshi EgawaDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA. Electronic address: egawat@wustl.edu.
Funding
TRAINING PROGRAM IN IMMUNOLOGY AND IMMUNOGENETICST32AI007163 · NIAID · WASHINGTON UNIVERSITY · PI Kenneth M Murphy, Kodi S Ravichandran · 1985 to 2026
$14.8MCIS-REGULATORY CIRCUITS FOR ILC FUNCTION AND PLASTICITYR01AI134035 · NIAID · WASHINGTON UNIVERSITY · PI MARCO COLONNA, Eugene M Oltz · 2018 to 2026
$4.8MThe transcription factor c-MYC in lymphocyte expansion and restriction of stemnessR01AI130152 · NIAID · WASHINGTON UNIVERSITY · PI Takeshi Egawa · 2017 to 2026
$4.6MEnhancing the Effectiveness of Immunotherapies by T Cell Epigenetic ReprogrammingR01AI170926 · NIAID · OHIO STATE UNIVERSITY · PI Hazem E. Ghoneim · 2023 to 2026
$2.6MMolecular mechanisms of CD8 T cell fate decision instructed by cytokine signalingR01AI176664 · NIAID · WASHINGTON UNIVERSITY · PI Takeshi Egawa · 2024 to 2026
$1.8MBuilding an atlas of B cell mediated protective immunity to alphavirusesK08AI187716 · NIAID · WASHINGTON UNIVERSITY · PI Saravanan Raju · 2025 to 2026
$340kCD8 T cell fate decision instructed by IL-2R56AI167361 · NIAID · WASHINGTON UNIVERSITY · PI EGAWA, TAKESHI · 2023 to 2023
$300kDefining the regulation and regulatory mechanisms of TCF-1 in CD8+ T cell differentiationF31AI174696 · NIAID · WASHINGTON UNIVERSITY · PI MURPHY, MAEGAN · 2023 to 2025
$104kNIAID NIH HHS F31 AI174696NIAID NIH HHS K08 AI187716NIAID NIH HHS R01 AI130152NIAID NIH HHS R01 AI134035NIAID NIH HHS R01 AI170926NIAID NIH HHS R01 AI176664NIAID NIH HHS R56 AI167361NIAID NIH HHS T32 AI007163
Abstract
During differentiation of CD8
Indexed as
CD8-Positive T-LymphocytesHepatocyte Nuclear Factor 1-alphaImmunologic MemoryMemory T CellsPositive Regulatory Domain I-Binding Factor 1T Cell Transcription Factor 1AnimalsCell DifferentiationCell ProliferationMiceMice, Inbred C57BLMice, KnockoutMice, TransgenicHepatocyte Nuclear Factor 1-alphaHnf1a protein, mousePositive Regulatory Domain I-Binding Factor 1Prdm1 protein, mouseT Cell Transcription Factor 1Blimp1effector differentiationT cell exhaustionT cell memoryTCF-1
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.